ZOLL Medical Receives 2009 North American Healthcare Innovation Award from Frost & Sullivan

CHELMSFORD, Mass., Nov 17, 2009 (BUSINESS WIRE) --
ZOLL | Quote | Chart | News | PowerRating -- ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical
devices and related software solutions, announced today that it has
received Frost & Sullivan's 2009 North American Healthcare Innovation
Award. ZOLL was recognized by Frost & Sullivan as a global leader in
defibrillation and resuscitation for its solutions that have
revolutionized critical care and advanced the practice of resuscitation
through pacing, defibrillation,
circulation,
data management, and fluid
resuscitation.

"ZOLL is driving innovation to accelerate a new level of care in the
diagnosis, treatment and management of cardiac arrest, which results in
better clinical outcomes and quality of life for patients," said Gary
Burk, Frost & Sullivan analyst. "Being acutely aware of the critical
care space and overall healthcare trends, ZOLL has continuously
delivered integrated solutions that encompass all facets of lifesaving
resuscitation."

"ZOLL's integrated critical care product portfolio provides cutting-edge
solutions that meet the growing demands of the ever-changing market
landscape to assist first responders, healthcare professionals,
government entities, military, and lay rescuers," said Burk.

"This Frost & Sullivan Award reinforces our vision of improving the
outcomes from sudden cardiac arrest, the leading cause of unexpected
death worldwide," said Jonathan A. Rennert, President of ZOLL. "Our key
strength has been our continued focus on advancing resuscitation
technology, and we've made significant strides with such industry
breakthroughs as Real CPR Help(R) and See-Thru CPR(R).
We've also broadened our reach into data management and beyond
resuscitation into temperature management for future growth for
improving patient care."

For the Healthcare Innovation Award, the following criteria were used to
benchmark ZOLL Medical's performance against key competitors:

--
Breakthrough approach / degree of differentiation innovation compared
to other market participants

--
Product innovation in terms of unique or revolutionary technology

--
Penetration rate of new markets

--
Significance of innovation in the industry

--
Leading proactive initiatives to improve value to customers

--
Advancement of the industry through research

--
Implementation of a new or unique pricing strategy

--
Implementation of a new or unique marketing strategy

--
Creating new venues, such as online services, for an established
product

Highlights of ZOLL's Portfolio for Strengthening Resuscitation Care

All of ZOLL's AEDs and defibrillators include Real CPR Help(R),
real-time CPR feedback to give rescuers to the proper rate and depth of
chest compressions. The R Series(R), E Series(R), and
AED Pro(R) offer See-Thru CPR(R), industry-unique
filtering technology that allows professional rescuers to view a
patient's underlying cardiac rhythm, by filtering CPR artifact during
resuscitation efforts. ZOLL's AutoPulse(R) is a revolutionary
non-invasive cardiac support pump that moves more blood more
consistently than possible with manual chest compressions. The LifeVest(R)
Wearable Defibrillator is the world's first and only wearable automatic
defibrillator and has a 98% first shock success rate. Most recently,
ZOLL has expanded its critical care portfolio to include Intravascular
Temperature Management Systems, which provide precise and rapid control
of a patient's core temperature for both cooling and warming
applications.

This integrated critical care portfolio includes:

--
AED Plus(R) Automated External Defibrillator

--
AED Pro(R)Automated External Defibrillator

--
R Series(R) Defibrillators

--
AutoPulse(R) Non-Invasive Cardiac Support Pump

--
CodeNet(R) Resuscitation Data Management System

--
Defibrillator Electrodes

--
LifeVest(R) Wearable Defibrillator

--
PocketCPR(R) Personal CPR Coaching Device

--
Intravascular Temperature Management (IVTM(TM))

--
SurePower(TM) Defibrillator Battery System

--
M Series(R) CCT Defibrillator

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth,
innovation and leadership. The Company's Growth Partnership Service
provides the CEO and the CEO's Growth Team with disciplined research and
best practice models to drive the generation, evaluation and
implementation of powerful growth strategies. Frost & Sullivan leverages
almost 50 years of experience in partnering with Global 1000 companies,
emerging businesses and the investment community from 31 offices on six
continents. To join our Growth Partnership, please visit www.frost.com.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and
software solutions that help advance emergency care and save lives,
while increasing clinical and operational efficiencies. With products
for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management,
ZOLL provides a comprehensive set of technologies which help clinicians,
EMS and fire professionals, and lay rescuers treat victims needing
resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company
for the past three years, ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois, Massachusetts,
Pennsylvania, and Rhode Island. More than 400 direct sales and service
representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the
globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including
statements regarding the future business of the Company, and other
statements contained herein regarding matters that are not historical
facts, are "forward-looking" statements (as defined in the Private
Securities Litigation Reform Act of 1995). Because such statements are
subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include, but are
not limited to, those factors discussed in the section entitled "Risk
Factors" in the Company's Quarterly Report on Form 10-Q filed with the
SEC on August 7, 2009. You should not place undue reliance on the
forward-looking statements in this press release, and the Company
disavows any obligation to update or supplement those statements in the
event of any changes in the facts, circumstances, or expectations that
underlie those statements.

(C)2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road,
Chelmsford, MA 01824-4105. ZOLL, AutoPulse, AED Plus, AED Pro, CodeNet,
E Series, Life Band, M Series, PocketCPR, R Series, Real CPR Help, and
See-Thru CPR are registered trademarks of ZOLL Medical Corporation. IVTM
and SurePower are trademarks of ZOLL Medical Corporation. All product
names are the property of their respective owners.

SOURCE: ZOLL Medical Corporation

ZOLL Medical Corporation 
INVESTOR CONTACT: 
A. Ernest Whiton, +1 978-421-9655 
Chief Financial Officer 
or 
MEDIA CONTACT: 
Diane Egan, +1 978-421-9637 
degan@zoll.com

For full details on (FRSU) FRSU. (FRSU) has Short Term PowerRatings at TradingMarkets. Details on (FRSU) Short Term PowerRatings is available at This Link.

For full details on Zoll Medical Corporation (ZOLL) ZOLL. Zoll Medical Corporation (ZOLL) has Short Term PowerRatings at TradingMarkets. Details on Zoll Medical Corporation (ZOLL) Short Term PowerRatings is available at This Link.